Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.6567
Abstract: Key Points Question Is use of targeted disease-modifying antirheumatic drugs associated with risk of Alzheimer disease and related dementia (ADRD)? Findings In this cohort study including 22 569 propensity score–matched patient pairs, initiation of inhibitors of… read more here.
Keywords: risk alzheimer; disease; targeted disease; disease modifying ... See more keywords
Evaluation of liver parenchyma with shear wave elastography in patients with rheumatoid arthritis receiving disease‐modifying antirheumatic drug therapy
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Ultrasound"
DOI: 10.1002/jcu.23847
Abstract: Methotrexate (MTX) and leflunomide (LEF) play fundamental roles in rheumatoid arthritis (RA) treatment and require proper monitoring of side effects. Concerns about MTX/LEF‐related liver fibrosis (LF) in patients with RA remain unclear. This study investigated… read more here.
Keywords: shear wave; wave elastography; rheumatoid arthritis; antirheumatic drug ... See more keywords
Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011
Sign Up to like & getrecommendations! Published in 2018 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-018-1321-4
Abstract: SummaryBackgroundRheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed… read more here.
Keywords: modifying antirheumatic; drug survival; disease modifying; biological disease ... See more keywords
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Sign Up to like & getrecommendations! Published in 2022 at "Dermatology and Therapy"
DOI: 10.1007/s13555-022-00713-1
Abstract: There is an increasing trend of malignancy worldwide. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones for the treatment of immune-mediated inflammatory diseases (IMIDs), but risk of malignancy is a major concern for patients receiving DMARDs.… read more here.
Keywords: conventional synthetic; antirheumatic drugs; disease modifying; oral conventional ... See more keywords
Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug.
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead075
Abstract: OBJECTIVES This study aimed to clarify the usefulness of screening for malignancies using computed tomography (CT) before the initiation of biologics and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with active rheumatoid arthritis (RA).… read more here.
Keywords: computed tomography; malignancy; disease modifying; modifying antirheumatic ... See more keywords
Comparative effectiveness of disease modifying antirheumatic drugs for patients with cardiac sarcoidosis.
Sign Up to like & getrecommendations! Published in 2024 at "Rheumatology"
DOI: 10.1093/rheumatology/keae692
Abstract: OBJECTIVES We aimed to evaluate the comparative efficacy of disease modifying antirheumatic drugs (DMARDs) for patients with cardiac sarcoidosis. METHODS We performed a retrospective cohort study of new users of methotrexate, mycophenolate, or azathioprine for… read more here.
Keywords: antirheumatic drugs; cardiac sarcoidosis; patients cardiac; disease modifying ... See more keywords
Comparison of the Efficacy and Safety of Disease‐Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta‐Analysis
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and Translational Science"
DOI: 10.1111/cts.70156
Abstract: There are several disease‐modifying antirheumatic drugs currently available to treat rheumatoid arthritis (RA). However, the optimal combination therapy with methotrexate for treating RA remains unclear. We aimed to identify combination therapies with high‐efficacy and safety… read more here.
Keywords: antirheumatic drugs; combination; efficacy; disease modifying ... See more keywords
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2016-210715
Abstract: Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles… read more here.
Keywords: modifying antirheumatic; disease modifying; disease; management ... See more keywords
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223356
Abstract: Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods An international task force was formed and solicited three systematic literature research activities… read more here.
Keywords: antirheumatic drugs; disease; rheumatoid arthritis; management ... See more keywords
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223636
Abstract: Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. Methods Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi,… read more here.
Keywords: antirheumatic drugs; biological disease; disease modifying; modifying antirheumatic ... See more keywords
The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Internal Medicine"
DOI: 10.2169/internalmedicine.9600-22
Abstract: Objective Sarcopenia is characterized by a loss of muscle mass and strength, which leads to frailty and mortality. Rheumatoid arthritis (RA) is considered to be a cause of sarcopenia. The present study assessed the effectiveness… read more here.
Keywords: disease; rheumatoid arthritis; status; biological disease ... See more keywords